We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov
ClinicalTrials.gov Menu

A Phase 1 Study To Investigate The Pharmacokinetics, Safety And Tolerability Of CP-601,927 In Healthy Japanese Subjects

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01396135
Recruitment Status : Withdrawn
First Posted : July 18, 2011
Last Update Posted : September 7, 2011
Sponsor:
Information provided by (Responsible Party):

July 14, 2011
July 18, 2011
September 7, 2011
August 2011
October 2011   (Final data collection date for primary outcome measure)
  • Cmax, AUClast, AUC0-12, Tmax and as data permit AUCinf, t1/2, CL/F, Vd/F after single dose of 1 mg CP-601,927 [ Time Frame: 0,0.5,1,2,4,6,8,12,14,16,24,36,48 hours post-dose ]
  • Cmax, AUClast, AUC0-12, Tmax and as data permit AUCinf, t1/2, CL/F, Vd/F after single dose of 2 mg CP-601,927 [ Time Frame: 0,0.5,1,2,4,6,8,12,14,16,24,36,48 hours post-dose ]
  • Cmax, AUClast, AUC0-12, Tmax and as data permit AUCinf, t1/2, CL/F, Vd/F after single dose of 3 mg CP-601,927 [ Time Frame: 0,0.5,1,2,4,6,8,12,14,16,24,36,48 hours post-dose ]
  • Ctrough, Cmax, AUC0-12, Tmax and as data permit t1/2, CL/F and Rac (accumulation ratio) based on Cmax and AUC0-12 after multiple doses of CP-601,927 given as 2 mg BID (4mg/day) for 7 days [ Time Frame: Day1-7 ]
  • Suicidality assessment after single dose of 1 mg CP-601,927 [ Time Frame: Day 0, 0 and 2 hours post-dose ]
  • Suicidality assessment after single dose of 2 mg CP-601,927 [ Time Frame: Day 0, 0 and 2 hours post-dose ]
  • Suicidality assessment after single dose of 3 mg CP-601,927 [ Time Frame: Day 0, 0 and 2 hours post-dose ]
  • Suicidality assessment after multiple doses of CP-601,927 given as 2 mg BID (4mg/day) for 7 days [ Time Frame: Day1-7 ]
Same as current
Complete list of historical versions of study NCT01396135 on ClinicalTrials.gov Archive Site
Not Provided
Not Provided
Not Provided
Not Provided
 
A Phase 1 Study To Investigate The Pharmacokinetics, Safety And Tolerability Of CP-601,927 In Healthy Japanese Subjects
A Phase 1, Randomized, Subject- And Investigator-Blind, Sponsor-Open, Placebo-Controlled, Single- And Multiple-Dose Study To Investigate The Pharmacokinetics, Safety And Tolerability Of CP-601,927 In Healthy Japanese Subjects
This Phase 1 study is the first clinical trial to be conducted in Japanese subjects. The pharmacokinetics, safety and tolerability of single and multiple doses of CP-601,927 will be evaluated in Japanese, healthy, non-smoking subjects.
Not Provided
Interventional
Phase 1
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Basic Science
Healthy
  • Drug: CP-601,927
    Single dose of 1 mg CP-601,927 given as oral 1 mg tablets
  • Drug: CP-601,927
    Single dose of 2 mg CP-601,927 given as oral 1 mg tablets
  • Drug: CP-601,927
    Single dose of 3 mg CP-601,927 given as oral 1 mg tablets
  • Drug: Placebo
    Single dose of placebo given as a matching number of oral tablets
  • Drug: CP-601,927
    Multiple doses of CP-601,927 given as 2 mg BID (4 mg/day) as oral 1 mg tablets for 7 days
  • Drug: Placebo
    Multiple doses of placebo given as a matching number of oral tablets
  • Experimental: Single dosing
    Single doses of CP-601,927 (1, 2 or 3 mg) or placebo
    Interventions:
    • Drug: CP-601,927
    • Drug: CP-601,927
    • Drug: CP-601,927
    • Drug: Placebo
  • Experimental: Multiple dosing
    Multiple doses of CP-601,927 (2 mg BID, 4mg/day) or placebo
    Interventions:
    • Drug: CP-601,927
    • Drug: Placebo
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
19
October 2011
October 2011   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Healthy male and/or female Japanese subjects between the ages of 18 and 55 years, inclusive.
  • Japanese defined as being able to document that all 4 grandparents were Japanese and were born in Japan.
  • Body Mass Index (BMI) of 17.5 to 30.5 kg/m2; and a total body weight >50 kg (110 lbs).

Exclusion Criteria:

  • Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease (including drug allergies, but excluding untreated, asymptomatic, seasonal allergies at the time of dosing).
  • Females of childbearing potential.
  • Subjects with regular (daily or weekly) use of tobacco products or nicotine currently or within the past 6 months. Subjects with urine cotinine concentrations >100 ng/mL at any time during the study will be excluded.
Sexes Eligible for Study: All
18 Years to 55 Years   (Adult)
Yes
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
 
NCT01396135
A3331019
No
Not Provided
Not Provided
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
September 2011

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP